Despite advances in management, infections with bacterial, viral, and fungal pathogens remain among the most common causes of mortality in hematopoietic stem cell transplantation (HCT). Performance gaps exist in the management of recurrent Clostridioides infections, prevention of cytomegalovirus infections, recognition of CMV infections as a risk factor for fungal infections, and management of hospital-acquired and ventilator-acquired bacterial pneumonia. This activity discusses evidence-based approaches to management of these infections in the HCT setting, with a particular emphasis on interdisciplinary management.
Release Date: 2/24/2020
Expiration Date: 2/23/2021
Estimated Time to Complete the Activity: 1.5 hrs
Media: Interactive, text-based activity
Infections with bacterial, viral, and fungal pathogens remain significant drivers of mortality in HCT. Given the impact of profound immunosuppression on the risk for infection, infectious complications are a major concern in this population. Modifiable factors contributing to the performance gap include inadequate interdisciplinary care, entrenched treatment patterns, limitations of current guidelines in addressing strategies for the immunocompromised population, and competency gaps in integrating newer therapeutic options into the treatment paradigm, particularly pharmacologic optimization. This initiative is focused on addressing those performance/competency gaps.
Upon completing this activity, participants should be better able to:
This activity is directed to infectious disease physicians, critical care physicians, hospitalists, surgeons, pathologists, hematologists/oncologists, pharmacists, and other healthcare providers responsible for the prevention and management of infections in the HCT setting.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM); ProCE, Inc.; Terranova Medica, LLC; and the Society of Infectious Diseases Pharmacists Educational Center (SIDPECTM). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.
PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest or a commercial interest.
The following indicates the disclosure declaration information and the nature of those commercial relationships:
FACULTY DISCLOSURES
Carolyn Alonso, MD, FIDSA
FINANCIAL SUPPORT:
Alnylam Pharmaceuticals (salary [spouse]); Moderna Therapeutics (stock sale [spouse])
Vasilios Athans, PharmD, BCPS, BCIDP
No conflicts to disclose.
Dayna McManus, PharmD, BCPS, AQ-ID
No conflicts to disclose.
Jennifer L. Saullo, MD, PharmD
No conflicts to disclose.
Frank Tverdek, PharmD, BCPS, AQ-ID, CMQ
No conflicts to disclose.
Eduardo Yepez Guevara, MD
No conflicts to disclose.
PLANNING COMMITTEE DISCLOSURES
The PIM, ProCE, and Terranova Medica, LLC planners and managers have nothing to disclose. Melissa Johnson, PharmD, MHS, AAHIVP, of the SIDPEC, discloses the following: advisory board for Paratek; Astellas; Shionogi & Company, Ltd.; and Cidara Therapeutics; research support from Merck & Co., Inc. and Shionogi & Company, Ltd.; and royalties from UpToDate.
There are no fees for participating and receiving CME/CE credit for this activity. During the accreditation period, participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please follow the steps below:
Internet
To participate, you will need access to a computer (either MAC or PC), tablet, or smart phone, with a Chrome (version 22.0.1229.94 or greater) web browser, Firefox (version 3.6 or greater) web browser or an Internet Explorer (version 8.0 or greater) web browser, JavaScript enabled, connected to the Internet (high speed connection preferred).
Terranova Medica, LLC, PIM, and ProCE are committed to protecting the privacy of those who choose to participate in activities on funguscme.org. This information below describes our security policies for safeguarding personal information as well as the rationale for collection and use of personal information.
Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.
Collection and use of personal information
Terranova Medica, LLC, PIM, and ProCE do not transfer, sell, or share personal information with outside parties. We will not disclose the information unless required in a legal proceeding.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
There is no charge for this activity.
Jointly provided by Postgraduate Institute for Medicine; ProCE; SIDPEC; and Terranova Medica, LLC.
This activity is supported by an independent educational grant from Merck & Co., Inc.
For further information, contact Tom Davis by telephone or fax (877-276-4523), or by email (tdavis@terranovamedica.com).
If you have any questions regarding the CME/CE certification for this activity, please contact PIM at: inquiries@pimed.com or (303) 799-1930.
Copyright © 2020 PIM, Terranova Medica, and ProCE.
